INDEMNIFICATION AGREEMENTIndemnification Agreement • August 11th, 2022 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of __________, 201___ by and between OptiNose, Inc., a Delaware corporation (the “Corporation”), in its own name and on behalf of its direct and indirect subsidiaries, and __________________, an individual (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Corporation and Indemnitee covering the subject matter of this Agreement.
THIRD AMENDMENT TO NOTE PURCHASE AGREEMENTNote Purchase Agreement • August 11th, 2022 • OptiNose, Inc. • Pharmaceutical preparations
This Third Amendment to the Note Purchase Agreement (defined below) (this “Amendment”), dated as of August 10, 2022 (the “Effective Date”), is entered into by and among OPTINOSE US, INC., a Delaware corporation (the “Issuer”), OPTINOSE AS, a Norwegian private limited liability company with Norwegian business registration number 982 483 131, and OPTINOSE, INC., a Delaware corporation (the “Parent”), and the Purchasers (as defined in the Note Purchase Agreement) party to the Note Purchase Agreement as of the Effective Date and BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales, as Collateral Agent.
